RT Journal Article
SR Electronic
T1 EP057/#158 Real-world patient profiles, treatment patterns, and outcomes among recurrent, persistent, and metastatic cervical cancer patients
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A71
OP A71
DO 10.1136/ijgc-2022-igcs.148
VO 32
IS Suppl 3
A1 Gokhale, Mugdha
A1 Yu, Rebekah
A1 Monberg, Matthew
A1 Tekin, Cumhur
A1 Fan, Lin
A1 Declue, Rich
A1 Knapp, Keith
A1 Lal, Lincy
YR 2022
UL http://ijgc.bmj.com/content/32/Suppl_3/A71.2.abstract
AB Objectives Real-world evidence among advanced cervical cancer (aCC) patients in the US is limited. This study evaluated patient characteristics, treatment patterns, and clinical outcomes among aCC patients under routine clinical care.Methods This retrospective study used the ConcertAI Oncology Dataset which draws from US oncology electronic medical records. Patients were ≥18 years, diagnosed with persistent, recurrent, or metastatic cervical cancer, and initiated systemic anti-cancer therapy between August 2014 and June 2021. Descriptive statistics were generated for patient characteristics and treatments. Kaplan-Meier product limit estimator was used to characterize time on treatment and real-world overall survival (rwOS).Results There were 325 patients with median age 51.5 years, 70.5% were White, and 47.7% were stage IVB at diagnosis. About 68.0% initiated bevacizumab in first line (1L) (Bev1L), 10.2% in 2L/3L (Bev2L/3L), and 21.8% did not receive bevacizumab (NoBev). The NoBev group was generally older and had more comorbidities, compared to patients on bevacizumab (table 1). Overall, the most common regimen received in 1L was bevacizumab-carboplatin-paclitaxel (38.5%), with median duration 3.51 months, followed by bevacizumab-cisplatin-paclitaxel (19.7%) with median duration 3.48 months, and carboplatin-paclitaxel (10.5%) with median duration 2.31 months. Median rwOS from 1L start was 16.5 months [95% CI:14.2, 19.9] overall, and generally higher in patients receiving bevacizumab (Bev1L 17.9 [14.5, 21.4] months, Bev2L/3L 16.0 [10.8, 43.6] months, and NoBev 10.5 [7.4, 32.7] months).View this table:Abstract EP057/#158 Table 1 Conclusions This study highlights burden of disease and unmet need for specific treatments in the real-world recurrent, persistent, and metastatic cervical cancer patients in the US.